Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patiromer in Children Under 12 Years of Age With Hyperkalaemia (EMERALD2)
NCT05766839Phase 2Recruiting
- Sponsor
- Vifor Pharma
- Start
- Apr 2025
- Primary completion
- Dec 2029
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 15
01
Overview
Phase 2, open-label, single-arm trial of patiromer in hyperkalemia, sponsored by Vifor Pharma. Primary endpoint: Change in potassium levels at Day 28. Started Apr 2025; status: recruiting.
02
Drugs
patiromer
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT05766839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05766839.